The filings point to a discounted equity raise ahead — dilution for existing holders. Next thing to watch: a 424B or offering 8-K.
Radar 94 (high attention) · dilution pressure high · listing risk high · governance risk low · runway 1.8 mo · strongest signal: Hearings panel (Aug 12, 2026)
What would confirm: 424B5/8-K announcing an offering, ATM sales disclosed in next 10-Q, or Form 4 sales by insiders ahead of it.
What would prove it wrong: Non-dilutive cash event (asset sale, grant, milestone payment), OCF turning positive, or shelf withdrawn (RW).
Direction is stated for existing shareholders (▼ more shares / survival or listing risk; ▲ insiders or holders buying). It is a characterization of the filings, not a forecast or a recommendation.
Independent filings stitched into a thesis, each with what would confirm and what would prove it wrong.
The filings point to a discounted equity raise ahead — dilution for existing holders. Next thing to watch: a 424B or offering 8-K. Cash need (runway < 6 months) coexists with live selling machinery (atm program, convertible note, equity line, warrant inducement). Base case is a discounted raise; the question is when, not if.
Listing is at risk and the usual cures are constrained. Next thing to watch: a reverse-split proxy, a hearings-panel 8-K, or a Form 25. Exchange deficiency plus a structural reason cure is hard (sub-$5M float, negative equity, no cash, or a reverse split already used). Under Nasdaq's 2026 rules (one reverse split per 12 months; $5M MVLS floor with no cure period from Sept 2026) the usual escape hatches are narrower.
Variable-priced paper is outstanding while the listing is under stress — the structure where dilution can accelerate. Watch the share count each quarter. Discount-priced or variable-priced securities are outstanding while the company is managing its listing with reverse splits/notices. Each conversion lowers the price, which lowers the next conversion price.
Cycurion (CYCU) closed an Aug. 3 warrant inducement transaction that generated $4.5M gross proceeds by inducing immediate exercise of Dec. 2025 warrants for 3.3M shares at $1.35/share (reduced from $3.62) – a 63% discount to the $3.62 original strike. As consideration, the company issued new unregistered warrants for 5.0M shares at $1.65 (150% coverage), exercisable only after shareholder approval, per the 8-K filed Aug. 3 and July 31 press release. The Q2 10-Q filed Aug. 14 shows $1.87M cash and $19.5M current liabilities as of June 30; with annualized burn of $12.5M, liquidity covered approximately 1.8 months at that date (now 47 days stale). Shares outstanding jumped 141% from 10.7M (June 5) to 25.8M (Aug. 10), and the company has a Nasdaq hearings panel scheduled for Aug. 20 related to the minimum bid deficiency per July 24 and Aug. 12 press releases.
Runway = liquidity ÷ monthly operating burn at the latest reported period · balance sheet 47 days old. A financing after the balance-sheet date is the main reason a figure can be stale — check the timeline below for offerings since then.
Last 30 days of filing signals plus current balance-sheet flags, newest first. ▼ pressure · ▲ support · hover a score for its components; every row links to the filing.
| Date | Signal | Evidence | Score |
|---|---|---|---|
| Aug 14, 2026 | ▼ Going-concern language | “going concern periodic” language in 10-Q (10-Q) filed 2026-08-14 filing | 18 |
| Aug 12, 2026 | ▼ Hearings panel | “hearings panel” language in 8-K (EX-99.1) filed 2026-08-12 filing | 52 |
| Aug 12, 2026 | ▼ Delisting language | “delisting notice” language in 8-K (EX-99.1) filed 2026-08-12 filing | 32 |
| Aug 4, 2026 | ▼ Convertible note | “convertible note” language in 8-K (8-K) filed 2026-08-04 filing | 39 |
| Aug 4, 2026 | ▼ Unregistered sale | 8-K Item 3.02 filed 2026-08-04 (accepted 17:15 ET) filing | 32 |
| Aug 3, 2026 | ▼ Equity line | “equity line” language in 8-K (EX-10.1) filed 2026-08-03 filing | 51 |
| Aug 3, 2026 | ▼ Warrant inducement | “warrant inducement” language in 8-K (EX-99.1) filed 2026-08-03 filing | 43 |
| Aug 3, 2026 | ▼ ATM program | “atm” language in 8-K (EX-99.1) filed 2026-08-03 filing | 41 |
| Aug 3, 2026 | ▼ Unregistered sale | 8-K Item 3.02 filed 2026-08-03 (accepted 17:14 ET) filing | 34 |
| Aug 3, 2026 | ▼ Reverse split | “reverse split” language in 8-K (EX-4.1) filed 2026-08-03 filing | 32 |
| Jul 31, 2026 | ▼ Warrant inducement | “warrant inducement” language in 8-K (EX-99.2) filed 2026-07-31 filing | 43 |
| Jul 31, 2026 | ▼ ATM program | “atm” language in 8-K (EX-99.2) filed 2026-07-31 filing | 41 |
| Jul 24, 2026 | ▼ Hearings panel | “hearings panel” language in 8-K (EX-99.1) filed 2026-07-24 filing | 52 |
| Jul 24, 2026 | ▼ Minimum bid deficiency | “min bid” language in 8-K (EX-99.1) filed 2026-07-24 filing | 42 |
| Jul 24, 2026 | ▼ Delisting language | “delisting notice” language in 8-K (EX-99.1) filed 2026-07-24 filing | 32 |
| Jul 23, 2026 | ▼ Reverse split | “reverse split” language in 8-K (8-K) filed 2026-07-23 filing | 37 |
| Jul 23, 2026 | · Officer/director change | 8-K Item 5.02 filed 2026-07-23 (accepted 17:30 ET) filing | 25 |
| Jun 30, 2026 | ▼ Runway < 6 months | ~1.8 months runway: liquidity $1,873,287 as of 2026-06-30, burn $12,519,857/yr (annualized 180-day YTD operating cash flow [companyfacts]) filing | 46 |
| Jun 30, 2026 | ▼ Share count +25% | Shares outstanding 10,709,032 (2026-06-05) -> 25,840,335 (2026-08-10), +141% filing | 41 |
| Jun 30, 2026 | ▼ Cash < current liabilities | Liquidity $1,873,287 vs current liabilities $19,531,722 filing | 21 |
VIVS VivoSim Labs, INC. · HCWB HCW Biologics Inc. · BIAF bioAffinity Technologies, In · XHLD TEN Holdings, Inc. · VSEE VSEE HEALTH, INC. · OTLK Outlook Therapeutics, Inc. · screener →